Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Minor histocompatibility antigen TCR-T.

Blood advances·2026

Same author

Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.

Blood advances·2026

Same author

Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response.

Nature communications·2026

Same author

Novel R Shiny Tool for Survival Analysis With Time-Varying Covariate in Oncology Studies: Overcoming Biases and Enhancing Collaboration.

JCO clinical cancer informatics·2026

Same author

Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based Models.

JCO clinical cancer informatics·2026

Same author

Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARs.

Journal for immunotherapy of cancer·2025

Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026

Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026

Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026

Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026

Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026

Same journal

A step toward streamlining HIT diagnosis.

Blood·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 25, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Competition for CD19 binding may accelerate CAR efficacy

Alexandre V Hirayama¹, Marie Bleakley¹

¹Fred Hutchinson Cancer Center.

|February 27, 2025

Summary

No abstract available in PubMed .

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Related Experiment Videos

Last Updated: May 25, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018